Log in to search using one of your social media accounts:


Amylyx begins dosing in Phase II trial of AMX0035 for ALS

Amylyx Pharmaceuticals has begun dosing patients in the Phase II CENTAUR clinical trial of its therapeutic candidate, AMX0035, to treat those with amyotrophic lateral sclerosis (ALS).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news

Related Links:

Authors: Riera-Punet N, Martinez-Gomis J, Paipa A, Povedano M, Peraire M Abstract AIMS: To determine the effect of amyotrophic lateral sclerosis (ALS) on aspects of masticatory function and to assess the relationship between ALS and the prevalence of traumatic mucosal lesions caused by oral self-injury. METHODS: A total of 153 ALS patients and 23 control subjects participated in this cross-sectional study. Clinical characteristics including site of onset, medication, type of feeding, and use of noninvasive mechanical ventilation were recorded. The Diagnostic Criteria for Temporomandibular Disorders (DC/TMD) pro...
Source: Journal of Orofacial Pain - Category: ENT & OMF Tags: J Oral Facial Pain Headache Source Type: research
Publication date: 14 February 2018 Source:Neuroscience Letters, Volume 666 Author(s): Andrei B. Belousov, Hiroshi Nishimune, Janna V. Denisova, Joseph D. Fontes Neuronal gap junctional protein connexin 36 (Cx36) contributes to neuronal death following a range of acute brain insults such as ischemia, traumatic brain injury and epilepsy. Whether Cx36 contributes to neuronal death and pathological outcomes in chronic neurodegenerative diseases, such as amyotrophic lateral sclerosis (ALS), is not known. We show here that the expression of Cx36 is significantly decreased in lumbar segments of the spinal cord of both human ALS ...
Source: Neuroscience Letters - Category: Neuroscience Source Type: research
Microglial cell-associated neuroinflammation is considered as a potential contributor to the pathophysiology of sporadic amyotrophic lateral sclerosis. However, the specific role of microglia in the disease pa...
Source: Journal of Neuroinflammation - Category: Neurology Authors: Tags: Research Source Type: research
Publication date: January 2018 Source:Journal of Clinical Neuroscience, Volume 47 Author(s): Satoshi Yamashita, Tatsuya Nakama, Mitsuharu Ueda, Shoji Honda, En Kimura, Masaaki Konagaya, Yukio Ando Subacute myelo-optico-neuropathy (SMON) is a neurodegenerative disease that may be caused by overdose or prolonged oral administration of clioquinol. Recently, dysphagia has attracted attention as a complication of SMON. To investigate lingual control in SMON, we examined patients with SMON using assessments of maximum tongue pressure, compared with dysphagia-related diseases, such as sporadic inclusion body myositis (sIBM) and ...
Source: Journal of Clinical Neuroscience - Category: Neuroscience Source Type: research
AbstractDeregulated neurotrophin is an etiological factor in the pathology of neurodegenerative diseases (ND) that are clinically different entities but characterised by similar limb dysfunction. Earlier validation of peripheral biomarkers can provide significant translational benefit to ND patients. We analysed brain-derived neurotrophic factor (BDNF) –tropomyosin possessing tyrosine-related kinase (Trk B) and its key downstream proteins which are implicated in ND such as Parkinson’s disease (PD), amyotrophic lateral sclerosis (ALS) and ataxia. Blood from ND patients with PD, ALS and Ataxia with movement dysfu...
Source: Journal of Molecular Neuroscience - Category: Neuroscience Source Type: research
This article is protected by copyright. All rights reserved.
Source: Muscle and Nerve - Category: Internal Medicine Authors: Tags: Clinical Research Article Source Type: research
Source: Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration - Category: Neurology Authors: Source Type: research
Sebastian Peters, Eva Zitzelsperger, Sabrina Kuespert, Sabine Iberl, Rosmarie Heydn, Siw Johannesen, Susanne Petri, Ludwig Aigner, Dietmar R. Thal, Andreas Hermann, Jochen H. Weishaupt, Tim-Henrik Bruun, Ulrich Bogdahn
Source: Frontiers in Neurology - Category: Neurology Source Type: research
This article is protected by copyright. All rights reserved.
Source: Journal of Oral Rehabilitation - Category: Dentistry Authors: Tags: Original Article Source Type: research
Authors: Liu J, Wang LN Abstract Neurodegenerative movement disorders mainly include Parkinson's disease, atypical parkinsonisms, Huntington disease, and hereditary ataxia. Riluzole is the only drug approved by the US Food and Drug Administration for amyotrophic lateral sclerosis. The neuroprotective effects of riluzole have been observed in experimental models of neurodegenerative movement disorders. In this paper, we aimed to systematically analyze the efficacy and safety of riluzole for patients with neurodegenerative movement disorder. We searched the electronic databases such as PubMed, EMBASE, CINAHL, Cochran...
Source: Drug Delivery - Category: Drugs & Pharmacology Tags: Drug Deliv Source Type: research
More News: ALS | Clinical Trials | Pharmaceuticals